Immune Checkpoint Inhibitor Rechallenge in Classical Hodgkin Lymphoma: Efficacy and Safety Insights from an Off-Trial Cohort

MedXY Editorial Team•Sep 29, 2026•Hematology-Oncology

Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse event (irAE)-induced treatment interruption in classical Hodgkin lymphoma (cHL) is feasible and generally safe.
Progression-free survival (PFS) and duration of response (DOR) were not significantly different between patients who underwent ICI rechallenge and those who did not within the same treatment line.
Recurrent irAEs occurred in 20% of rechallenged patients, with recurrence of the same irAE in only 7%, indicating manageable safety signals.
In patients rechallenged at subsequent therapy lines, median PFS varied notably depending on prior response, highlighting the influence of disease status on outcomes.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse event (irAE)-induced treatment interruption in classical Hodgkin lymphoma (cHL) is feasible and generally safe.
Progression-free survival (PFS) and duration of response (DOR) were not significantly different between patients who underwent ICI rechallenge and those who did not within the same treatment line.
Recurrent irAEs occurred in 20% of rechallenged patients, with recurrence of the same irAE in only 7%, indicating manageable safety signals.
In patients rechallenged at subsequent therapy lines, median PFS varied notably depending on prior response, highlighting the influence of disease status on outcomes.